Gene therapy of inherited retinal degenerations: Prospects and challenges

Human Gene Therapy

Volumn 26, Issue 4, 2015, Pages 193-200

  Trapani, Ivana ^a   Banfi, Sandro ^a,b   Simonelli, Francesca ^c   Surace, Enrico M ^a,d   Auricchio, Alberto ^a,d  

^a TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^b Unit of Medical Genetics   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN; RHODOPSIN; RIBOZYME; RPE65 PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

CHOROIDEREMIA; DRUG SAFETY; GENE THERAPY; GENE TRANSFER; HUMAN; INHERITED RETINAL DEGENERATION; LEBER CONGENITAL AMAUROSIS; NONHUMAN; RETINA DEGENERATION; RETINITIS PIGMENTOSA; REVIEW; STARGARDT DISEASE; USHER SYNDROME; ANIMAL; CLINICAL TRIAL (TOPIC); GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; PATHOLOGY; RETINA; RETINAL DEGENERATION;

ANIMALIA;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; RETINA; RETINAL DEGENERATION; RHODOPSIN; TRANSDUCTION, GENETIC;

EID: 84928502581     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.030     Document Type: Review

References (108)

1. Sahel JA, Marazova K, Audo I. Clinical characteristics and current therapies for inherited retinal degenerations. Cold Spring Harb Perspect Med 2014;5:pii: a017111.
2. Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res 2010;29:335-375.
3. Dalkara D, Sahel JA. Gene therapy for inherited retinal degenerations. C R Biol 2014;337:185-192.
4. Dryja TP. Retinitis pigmentosa and stationary night blindness. In: OMMBID: The Online Metabolic and Molecular Bases of Inherited Disease. D Valle, AL Beaudet, B Vogelstein, KW Kinzler, SE Antonarakis, A Ballabio, KM Gibson and G Mitchell, eds. (McGraw-Hill Companies, New York, NY). Chap. 235, pp. 1-71.
5. Lewis RA, Allikmets R, Lupski JR. Inherited macular dystrophies and susceptibility to degeneration. In: OMMBID: The Online Metabolic and Molecular Bases of Inherited Disease. D Valle, AL Beaudet, B Vogelstein, KW Kinzler, SE Antonarakis, A Ballabio, KM Gibson and G Mitchell, eds. (McGraw-Hill Companies, New York, NY). Chap. 243, pp. 1-35.
6. Trapani I, Puppo A, Auricchio A. Vector platforms for gene therapy of inherited retinopathies. Prog Retin Eye Res 2014;43:108-128.
7. Sahel JA, Roska B. Gene therapy for blindness. Annu Rev Neurosci 2013;36:467-488.
8. Jacobson SG, Aleman TS, Cideciyan AV, et al. Identifying photoreceptors in blind eyes caused by RPE65 mutations: prerequisite for human gene therapy success. Proc Natl Acad Sci USA 2005;102:6177-6182.
9. Chung DC, Traboulsi EI. Leber congenital amaurosis: clinical correlations with genotypes, gene therapy trials update, and future directions. J AAPOS 2009;13:587-592.
10. Simonelli F, Ziviello C, Testa F, et al. Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients. Invest Ophthalmol Vis Sci 2007;48:4284-4290.
11. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012;130:9-24.
12. Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 2013;120:1283-1291.
13. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231-2239.
14. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009;20:999-1004.
15. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 2009;361:725-727.
16. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008;19:979-990.
17. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009; 374:1597-1605.
18. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248.
19. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18: 643-650.
20. Ashtari M, Cyckowski LL, Monroe JF, et al. The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest 2011;121:2160-2168.
21. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012;4:120ra115.
22. High KA. The gene therapy journey for hemophilia: are we there yet? Hematology 2012;2012:375-381.
23. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-2365.
24. Lok C. Curing blindness: vision quest. Nature 2014;513: 160-162.
25. Le Meur G, Stieger K, Smith AJ, et al. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 2007;14:292-303.
26. Conlon TJ, Deng WT, Erger K, et al. Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. Hum Gene Ther Clin Dev 2013;24:23-28.
27. Kong J, Kim SR, Binley K, et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther 2008;15:1311-1320.
28. Binley K, Widdowson P, Loader J, et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Invest Ophthalmol Vis Sci 2013;54: 4061-4071.
29. Zallocchi M, Binley K, Lad Y, et al. EIAV-based retinal gene therapy in the shaker1 mouse model for usher syndrome type 1B: development of UshStat. PLoS One 2014; 9:e94272.
30. Koilkonda RD, Yu H, Chou TH, et al. Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol 2014; 132:409-420.
31. Cwerman-Thibault H, Augustin S, Ellouze S, et al. Gene therapy for mitochondrial diseases: Leber hereditary optic neuropathy as the first candidate for a clinical trial. C R Biol 2014;337:193-206.
32. Maclaren RE, Groppe M, Barnard AR, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014;383:1129-1137.
33. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA 2013;110:E517-E525.
34. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001;28:92-95.
35. Annear MJ, Bartoe JT, Barker SE, et al. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function. Gene Ther 2011;18:53-61.
36. Narfstrom K, Katz ML, Bragadottir R, et al. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest Ophthalmol Vis Sci 2003;44:1663-1672.
37. Rattner A, Sun H, Nathans J. Molecular genetics of human retinal disease. Annu Rev Genet 1999;33:89-131.
38. Anderson DH, Fisher SK. The relationship of primate foveal cones to the pigment epithelium. J Ultrastruct Res 1979;67:23-32.
39. Cideciyan AV, Aguirre GK, Jacobson SG, et al. Pseudofovea formation after gene therapy for RPE65-LCA. Invest Ophthalmol Vis Sci 2015;56:526-537.
40. Stieger K, Cronin T, Bennett J, et al. Adeno-associated virus mediated gene therapy for retinal degenerative diseases. Methods in Mol Biol 2011;807:179-218.
41. Dalkara D, Kolstad KD, Caporale N, et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Molecular Ther 2009;17:2096-2102.
42. Park TK, Wu Z, Kjellstrom S, et al. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther 2009;16:916-926.
43. Kolstad KD, Dalkara D, Guerin K, et al. Changes in adeno-associated virus-mediated gene delivery in retinal degeneration. Hum Gene Ther 2010;21:571-578.
44. Vacca O, Darche M, Schaffer DV, et al. AAV-mediated gene delivery in Dp71-null mouse model with compromised barriers. Glia 2014;62:468-476.
45. Kay CN, Ryals RC, Aslanidi GV, et al. Targeting photoreceptors via intravitreal delivery using novel, capsidmutated AAV vectors. PLoS One 2013;8:e62097.
46. Petrs-Silva H, Dinculescu A, Li Q, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011;19:293-301.
47. Dalkara D, Byrne LC, Klimczak RR, et al. In vivodirected evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013;5:189ra176.
48. Mowat FM, Gornik KR, Dinculescu A, et al. Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach. Gene Ther 2014;21:96-105.
49. Bennett J, Wilson J, Sun D, et al. Adenovirus vectormediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Vis Sci 1994;35:2535-2542.
50. Kumar-Singh R. Barriers for retinal gene therapy: separating fact from fiction. Vis Res 2008;48:1671-1680.
51. Puppo A, Cesi G, Marrocco E, et al. Retinal transduction profiles by high-capacity viral vectors. Gene Ther 2014; 21:855-865.
52. Miyoshi H, Takahashi M, Gage FH, et al. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA 1997;94:10319-10323.
53. Takahashi M, Miyoshi H, Verma IM, et al. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J Virol 1999;73:7812-7816.
54. Hashimoto T, Gibbs D, Lillo C, et al. Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B. Gene Ther 2007;14:584-594.
55. Davis RJ, Tosi J, Janisch KM, et al. Functional rescue of degenerating photoreceptors in mice homozygous for a hypomorphic cGMP phosphodiesterase 6 b allele (Pde6bH620Q). Invest Ophthalmol Vis Sci 2008;49:5067-5076.
56. Nicoud M, Kong J, Iqball S, et al. Development of photoreceptor-specific promoters and their utility to investigate EIAV lentiviral vector mediated gene transfer to photoreceptors. J Gene Med 2007;9:1015-1023.
57. Auricchio A, Kobinger G, Anand V, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 2001;10:3075-3081.
58. Bainbridge JW, Stephens C, Parsley K, et al. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther 2001;8: 1665-1668.
59. Bemelmans AP, Bonnel S, Houhou L, et al. Retinal cell type expression specificity of HIV-1-derived gene transfer vectors upon subretinal injection in the adult rat: influence of pseudotyping and promoter. J Gene Med 2005;7:1367-1374.
60. Balaggan KS, Binley K, Esapa M, et al. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J Gene Med 2006;8:275-285.
61. Gruter O, Kostic C, Crippa SV, et al. Lentiviral vectormediated gene transfer in adult mouse photoreceptors is impaired by the presence of a physical barrier. Gene Ther 2005;12:942-947.
62. Pang J, Cheng M, Haire SE, et al. Efficiency of lentiviral transduction during development in normal and rd mice. Mol Vis 2006;12:756-767.
63. Pang J, Cheng M, Stevenson D, et al. Adenoviralmediated gene transfer to retinal explants during development and degeneration. Exp Eye Res 2004;79: 189-201.
64. Adijanto J, Naash MI. Nanoparticle-based technologies for retinal gene therapy. Eur J Pharm Biopharm 2015. [Epub ahead of print]
65. Han Z, Conley SM, Makkia RS, et al. DNA nanoparticlemediated ABCA4 delivery rescues Stargardt dystrophy in mice. J Clin Invest 2012;122:3221-3226.
66. Cai X, Conley SM, Nash Z, et al. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J 2010;24:1178-1191.
67. Cai X, Nash Z, Conley SM, et al. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One 2009;4: e5290.
68. Allocca M, Doria M, Petrillo M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectorsresults in effective gene delivery in mice. J Clin Invest 2008;118:1955-1964.
69. Lopes VS, Boye SE, Louie CM, et al. Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus. Gene Ther 2013;20:824-833.
70. Dong B, Nakai H, Xiao W. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther 2010;18:87-92.
71. Hirsch ML, Agbandje-McKenna M, Samulski RJ. Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus. Mol Ther 2010;18:6-8.
72. Hirsch ML, Li C, Bellon I, et al. Oversized AAV transduction is mediated via a DNA-PKcs-independent, Rad51Cdependent repair pathway. Mol Ther 2013;21:2205-2216.
73. Lai Y, Yue Y, Duan D. Evidence for the failure of adenoassociated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther 2010;18:75-79.
74. Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther 2010;18:80-86.
75. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998;72:8568-8577.
76. Yan Z, Zhang Y, Duan D, et al. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA 2000;97:6716-6721.
77. Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther 2001;4:383-391.
78. Ghosh A, Yue Y, Lai Y, et al. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther 2008;16: 124-130.
79. Halbert CL, Allen JM, Miller AD. Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat Biotechnol 2002;20:697-701.
80. Zhang Y, Yue Y, Li L, et al. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum Mol Genet 2013;22:3720-3729.
81. Lopes VS, Boye SE, Louie CM, et al. Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus. Gene Ther 2013;20:824-833.
82. Trapani I, Colella P, Sommella A, et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med 2014;6:194-211.
83. Colella P, Trapani I, Cesi G, et al. Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors. Gene Ther 2014;21:450-456.
84. Zhang Y, Duan D. Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Hum Gene Ther 2012;23:98-103.
85. Lai Y, Yue Y, Liu M, et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 2005;23:1435-1439.
86. Lostal W, Bartoli M, Bourg N, et al. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 2010;19:1897-1907.
87. Odom GL, Gregorevic P, Allen JM, et al. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol Ther 2011;19: 36-45.
88. Chao H, Sun L, Bruce A, et al. Expression of human factor VIII by splicing between dimerized AAV vectors. Mol Ther 2002;5:716-722.
89. Reich SJ, Auricchio A, Hildinger M, et al. Efficient trans-splicing in the retina expands the utility of adenoassociated virus as a vector for gene therapy. Hum Gene Ther 2003;14:37-44.
90. Dyka FM, Boye SL, Chiodo VA, et al. Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A. Hum Gene Ther Methods 2014;25:166-177.
91. LaVail MM, Yasumura D, Matthes MT, et al. Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc Natl Acad Sci USA 2000;97:11488-11493.
92. Lewin AS, Drenser KA, Hauswirth WW, et al. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med 1998; 4:967-971.
93. Tessitore A, Parisi F, Denti MA, et al. Preferential silencing of a common dominant rhodopsin mutation does not inhibit retinal degeneration in a transgenic model. Mol Ther 2006;14:692-699.
94. Gorbatyuk M, Justilien V, Liu J, et al. Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme. Exp Eye Res 2007; 84:44-52.
95. Gorbatyuk M, Justilien V, Liu J, et al. Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vis Res 2007;47:1202-1208.
96. Gorbatyuk MS, Pang JJ, Thomas J Jr., et al. Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach. Mol Vis 2005;11:648-656.
97. Chadderton N, Millington-Ward S, Palfi A, et al. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol Ther 2009;17:593-599.
98. O'ReillyM, Palfi A, Chadderton N, et al. RNA interferencemediated suppression and replacement of human rhodopsin in vivo. Am J Hum Genet 2007;81:127-135.
99. Mao H, Gorbatyuk MS, Rossmiller B, et al. Long-term rescue of retinal structure and function by rhodopsin RNA replacement with a single adeno-associated viral vector in P23H RHO transgenic mice. Hum Gene Ther 2012;23: 356-366.
100. Millington-Ward S, Chadderton N, O'Reilly M, et al. Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther 2011;19:642-649.
101. Mussolino C, Sanges D, Marrocco E, et al. Zinc-fingerbased transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Mol Med 2011;3: 118-128.
102. Roof DJ, Korenbrot JI, Heuser JE. Surfaces of rod photoreceptor disk membranes: light-activated enzymes. J Cell Biol 1982;95:501-509.
103. Kabadi AM, Gersbach CA. Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression. Methods 2014;69:188-197.
104. Jacobson SG, Cideciyan AV, Peshenko IV, et al. Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptorvision correlates with biochemical properties of the mutants. Hum Mol Genet 2013;22:168-183.
105. Lipinski DM, Thake M, MacLaren RE. Clinical applications of retinal gene therapy. Prog Retin Eye Res 2013;32:22-47.
106. Molday RS, Zhong M, Quazi F. The role of the photoreceptor ABC transporter ABCA4 in lipid transport and Stargardt macular degeneration. Biochim Biophys Acta 2009;1791:573-583.
107. Ramamurthy V, Niemi GA, Reh TA, et al. Leber congenital amaurosis linked to AIPL1: a mouse model reveals destabilization of cGMP phosphodiesterase. Proc Natl Acad Sci USA 2004;101:13897-13902.
108. O'Reilly M, Kohn DB, Bartlett J, et al. Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012.HumGeneTher 2013;24:355-362.